TrialArthritis & rheumatology (Hoboken, N.J.)2017

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.

Frédéric Vanhoutte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.